SK284339B6 - Deriváty pyridopyranoazepínu, spôsob ich prípravy, liečivo a farmaceutická kompozícia s ich obsahom - Google Patents

Deriváty pyridopyranoazepínu, spôsob ich prípravy, liečivo a farmaceutická kompozícia s ich obsahom Download PDF

Info

Publication number
SK284339B6
SK284339B6 SK1242-2001A SK12422001A SK284339B6 SK 284339 B6 SK284339 B6 SK 284339B6 SK 12422001 A SK12422001 A SK 12422001A SK 284339 B6 SK284339 B6 SK 284339B6
Authority
SK
Slovakia
Prior art keywords
group
alkyl
hydrogen
compound
carbon atoms
Prior art date
Application number
SK1242-2001A
Other languages
English (en)
Slovak (sk)
Other versions
SK12422001A3 (sk
Inventor
Fr�D�Ric Galli
Samir Jegham
Alistair Lochead
Axelle Samson
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of SK12422001A3 publication Critical patent/SK12422001A3/sk
Publication of SK284339B6 publication Critical patent/SK284339B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK1242-2001A 1999-03-05 2000-03-01 Deriváty pyridopyranoazepínu, spôsob ich prípravy, liečivo a farmaceutická kompozícia s ich obsahom SK284339B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9902784A FR2790474B1 (fr) 1999-03-05 1999-03-05 Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
PCT/FR2000/000502 WO2000053608A1 (fr) 1999-03-05 2000-03-01 Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
SK12422001A3 SK12422001A3 (sk) 2002-04-04
SK284339B6 true SK284339B6 (sk) 2005-02-04

Family

ID=9542888

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1242-2001A SK284339B6 (sk) 1999-03-05 2000-03-01 Deriváty pyridopyranoazepínu, spôsob ich prípravy, liečivo a farmaceutická kompozícia s ich obsahom

Country Status (37)

Country Link
US (2) US6538003B1 (id)
EP (1) EP1161434B1 (id)
JP (1) JP4806123B2 (id)
KR (2) KR100768355B1 (id)
CN (1) CN1137894C (id)
AR (1) AR022820A1 (id)
AT (1) ATE231869T1 (id)
AU (1) AU764625B2 (id)
BG (1) BG65211B1 (id)
BR (1) BR0008763A (id)
CA (1) CA2372063C (id)
CO (1) CO5160250A1 (id)
CZ (1) CZ302259B6 (id)
DE (1) DE60001307T2 (id)
DK (1) DK1161434T3 (id)
EE (1) EE04497B1 (id)
ES (1) ES2191611T3 (id)
FR (1) FR2790474B1 (id)
HK (1) HK1040398B (id)
HR (1) HRP20010655B1 (id)
HU (1) HU228671B1 (id)
ID (1) ID30116A (id)
IL (2) IL145150A0 (id)
MX (1) MXPA01008972A (id)
NO (1) NO327119B1 (id)
NZ (1) NZ513561A (id)
PE (1) PE20001543A1 (id)
PL (1) PL201683B1 (id)
RS (1) RS49997B (id)
RU (1) RU2238273C2 (id)
SK (1) SK284339B6 (id)
TR (1) TR200102403T2 (id)
TW (1) TWI222975B (id)
UA (1) UA61164C2 (id)
UY (1) UY26048A1 (id)
WO (1) WO2000053608A1 (id)
ZA (1) ZA200106811B (id)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
BR0312297A (pt) 2002-07-18 2005-04-12 Cytos Biotechnology Ag Conjugados veìculos de hapteno e seu uso
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
CA2507502C (en) * 2002-12-06 2011-11-29 North Shore-Long Island Jewish Research Institute Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
US20090076059A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched dianicline
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
BRPI0820668A2 (pt) * 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
US8703775B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
CN102026995B (zh) * 2007-12-07 2014-10-29 Abbvie德国有限责任两合公司 5，6-二取代的羟吲哚衍生物和其用途
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
JP2011516489A (ja) 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
ES2396300T3 (es) 2008-11-19 2013-02-20 Envivo Pharmaceuticals, Inc. Tratamiento de trastornos cognitivos con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN102802620A (zh) * 2009-05-11 2012-11-28 英维沃医药有限公司 使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍
US9040568B2 (en) * 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
WO2011146511A1 (en) 2010-05-17 2011-11-24 Envivo Pharmaceuticals, Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301660D0 (en) * 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
JPH11512443A (ja) * 1995-09-22 1999-10-26 ノボ ノルディスク アクティーゼルスカブ 新規な置換アザ環式またはアザ二環式化合物
FR2761072B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de 2,3-dihydrofuro[3,2-b]pyridine, leur preparation et leur application en therapeutique
ATE254618T1 (de) * 1997-05-30 2003-12-15 Neurosearch As Spiro chinuclidin-derivate, ihre herstellung und verwendung
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
RU2238273C2 (ru) 2004-10-20
US20030187012A1 (en) 2003-10-02
HUP0201753A3 (en) 2004-12-28
HRP20010655A2 (en) 2002-08-31
CN1343208A (zh) 2002-04-03
HUP0201753A2 (en) 2002-09-28
EP1161434B1 (fr) 2003-01-29
IL145150A0 (en) 2002-06-30
FR2790474A1 (fr) 2000-09-08
DK1161434T3 (da) 2003-05-26
ZA200106811B (en) 2002-08-19
HK1040398B (zh) 2003-07-18
JP4806123B2 (ja) 2011-11-02
US6538003B1 (en) 2003-03-25
RS49997B (sr) 2008-09-29
PL201683B1 (pl) 2009-04-30
CA2372063A1 (en) 2000-09-14
PL352330A1 (en) 2003-08-11
UY26048A1 (es) 2000-09-29
US6908927B2 (en) 2005-06-21
HU228671B1 (en) 2013-05-28
EE200100470A (et) 2002-12-16
UA61164C2 (uk) 2003-11-17
FR2790474B1 (fr) 2001-04-06
AR022820A1 (es) 2002-09-04
ES2191611T3 (es) 2003-09-16
EE04497B1 (et) 2005-06-15
AU764625B2 (en) 2003-08-28
IL145150A (en) 2007-06-03
JP2002539129A (ja) 2002-11-19
HK1040398A1 (en) 2002-06-07
TWI222975B (en) 2004-11-01
NZ513561A (en) 2003-06-30
MXPA01008972A (es) 2002-03-27
BG105828A (bg) 2002-03-29
BR0008763A (pt) 2002-01-02
WO2000053608A1 (fr) 2000-09-14
CO5160250A1 (es) 2002-05-30
CN1137894C (zh) 2004-02-11
CZ20013102A3 (cs) 2002-01-16
NO20014270L (no) 2001-11-05
HRP20010655B1 (en) 2003-06-30
AU2922600A (en) 2000-09-28
BG65211B1 (bg) 2007-07-31
EP1161434A1 (fr) 2001-12-12
KR100768355B1 (ko) 2007-10-17
YU59601A (sh) 2004-03-12
CA2372063C (en) 2011-01-11
TR200102403T2 (tr) 2001-12-21
ID30116A (id) 2001-11-08
ATE231869T1 (de) 2003-02-15
KR20070086359A (ko) 2007-08-27
NO327119B1 (no) 2009-04-27
NO20014270D0 (no) 2001-09-03
PE20001543A1 (es) 2001-03-18
CZ302259B6 (cs) 2011-01-19
KR20010102492A (ko) 2001-11-15
DE60001307D1 (de) 2003-03-06
DE60001307T2 (de) 2003-12-11
SK12422001A3 (sk) 2002-04-04

Similar Documents

Publication Publication Date Title
SK284339B6 (sk) Deriváty pyridopyranoazepínu, spôsob ich prípravy, liečivo a farmaceutická kompozícia s ich obsahom
TWI221843B (en) Derivatives 1,4-diazabicyclo[3.2.2]nonane-4-carboxylates and carboxamides, their preparation and their therapeutic application
PL172852B1 (pl) Nowe pochodne piperydyny i sposób wytwarzania nowych pochodnych piperydyny PL PL
SK6772002A3 (en) New use and novel n-azabicyclo-amide derivatives
TW200303312A (en) 4-(Oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane derivatives, their preparation and their application in therapeutics
US6835730B2 (en) 4-heteroparyl-1,4-diazabicyclo[3.2.2]nonane, preparation and therapeutic use thereof
WO2004043960A1 (en) 1,4-diazabicyclo (3,2,2)nonane derivatives, preparation and therapeutical use thereof
KR101830447B1 (ko) 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
WO2007135120A1 (en) Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use
SK127699A3 (en) 2,3-dihydrofuro[3,2-b]pyridin, preparation and application thereof in therapy
US8557819B2 (en) Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics
EP0457243A1 (en) Novel tricyclic compounds
JP2009505971A (ja) ５−ピリジニル−１−アザビシクロ［３．２．１］オクタンの誘導体、この調製方法および治療におけるこの使用
US6656951B2 (en) 8-aza-bicyclo[3.2.1]octan-3-ol derivatives of 2,3-dihydro-1,4-benzodioxan as 5-HT1A antagonists
US20100076011A1 (en) Enantiomer-Pure Hexahydro-Pyrrolocyclopenta-Pyridine Derivatives
CZ200030A3 (cs) Deriváty 6-pyrrolidin-2-ylpyrindinů, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20150301